NASDAQ:ENSC Ensysce Biosciences (ENSC) Stock Price, News & Analysis $0.30 -0.02 (-5.60%) As of 12:31 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Ensysce Biosciences Stock (NASDAQ:ENSC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Ensysce Biosciences alerts:Sign Up Key Stats Today's Range$0.30▼$0.3250-Day Range$0.28▼$0.6352-Week Range$0.23▼$2.75Volume236,083 shsAverage Volume4.92 million shsMarket Capitalization$2.83 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Ensysce Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel prodrug therapies aimed at improving pain management and addressing opioid misuse. Leveraging its proprietary prodrug platform, the company designs drug candidates that convert into active pharmaceuticals through specific enzymatic action, providing controlled-release profiles and built-in abuse deterrence features. The company’s lead product candidate, ENS100, is an investigational oral prodrug of hydrocodone engineered to reduce the potential for misuse and abuse compared to immediate-release opioid formulations. Ensysce is advancing ENS100 through preclinical studies and regulatory interactions, with the goal of submitting an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA). Beyond pain management, the platform underpins additional pipeline programs targeting other central nervous system indications where controlled drug delivery may enhance therapeutic benefit and safety. Founded with a mission to address critical public health challenges, Ensysce Biosciences operates primarily in the United States and engages in collaborative partnerships to support its research and development activities. The company holds a portfolio of issued patents and pending applications covering its enzyme-activated prodrug technologies, reflecting a commitment to innovation in the design of safer pharmaceutical therapies.AI Generated. May Contain Errors. Read More Ensysce Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks26th Percentile Overall ScoreENSC MarketRank™: Ensysce Biosciences scored higher than 26% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingEnsysce Biosciences has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageEnsysce Biosciences has only been the subject of 1 research reports in the past 90 days.Read more about Ensysce Biosciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Ensysce Biosciences are expected to grow in the coming year, from ($3.54) to ($0.20) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ensysce Biosciences is -0.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ensysce Biosciences is -0.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.58% of the float of Ensysce Biosciences has been sold short.Short Interest Ratio / Days to CoverEnsysce Biosciences has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Ensysce Biosciences has recently decreased by 17.99%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEnsysce Biosciences does not currently pay a dividend.Dividend GrowthEnsysce Biosciences does not have a long track record of dividend growth. News and Social Media3.6 / 5News Sentiment0.75 News SentimentEnsysce Biosciences has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Ensysce Biosciences this week, compared to 1 article on an average week.Search Interest5 people have searched for ENSC on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days. Company Ownership0.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Ensysce Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders2.80% of the stock of Ensysce Biosciences is held by insiders.Percentage Held by Institutions5.63% of the stock of Ensysce Biosciences is held by institutions.Read more about Ensysce Biosciences' insider trading history. Receive ENSC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ensysce Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ENSC Stock News HeadlinesENSC advancing testing and expanding potentialMay 18, 2026 | msn.comEnsysce Biosciences (ENSC) price target decreased by 34.79% to 16.78May 15, 2026 | msn.comSneak Peek: Wall Street’s Little Black BookTom Busby, pro trader and CEO of the Diversified Trading Institute, spent years building a collection of what he calls the safest and most powerful trading strategies ever created. He's now offering a free download of 'The Little Black Book of Trading Strategies' - covering approaches designed to help traders target stronger returns while keeping risk in check.May 22 at 1:00 AM | DTI Trader (Ad)Ensysce Biosciences Announces Expansion of Patent Protection for Groundbreaking MPAR Overdose Protection TechnologyMay 13, 2026 | finanznachrichten.deENSC Making Great Strides Toward CommercializationMarch 31, 2026 | msn.comTiny Pain-Focused Biotech Ensysce Biosciences Surges Amid Strategic ReviewFebruary 27, 2026 | benzinga.comENSC expands its global patent portfolioJanuary 21, 2026 | msn.comEnsysce Biosciences Shareholders Approve Key Corporate ActionsJanuary 10, 2026 | theglobeandmail.comSee More Headlines ENSC Stock Analysis - Frequently Asked Questions How have ENSC shares performed this year? Ensysce Biosciences' stock was trading at $0.92 at the beginning of 2026. Since then, ENSC shares have decreased by 66.8% and is now trading at $0.3050. How were Ensysce Biosciences' earnings last quarter? Ensysce Biosciences, Inc. (NASDAQ:ENSC) issued its quarterly earnings data on Friday, May, 15th. The company reported ($0.52) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.73) by $0.21. The business earned $0.96 million during the quarter, compared to analysts' expectations of $1 million. Ensysce Biosciences had a negative trailing twelve-month return on equity of 766.45% and a negative net margin of 250.39%. When did Ensysce Biosciences' stock split? Shares of Ensysce Biosciences reverse split before market open on Friday, March 31st 2023.The 1-12 reverse split was announced on Friday, March 31st 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, March 31st 2023. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. How do I buy shares of Ensysce Biosciences? Shares of ENSC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Ensysce Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ensysce Biosciences investors own include Predictive Oncology (POAI), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Abbott Laboratories (ABT), Meta Platforms (META), Insulet (PODD) and Broadcom (AVGO). Company Calendar Last Earnings5/15/2026Today5/22/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (7m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 ENSC's financial health is in the Red zone, according to TradeSmith. ENSC has been in this zone for over 7 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ENSC CIK1716947 Webensysce.com Phone858-263-4196FaxN/AEmployees10Year FoundedN/AProfitability EPS (Trailing Twelve Months)($3.35) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$10.18 million Net Margins-250.39% Pretax Margin-250.39% Return on Equity-766.45% Return on Assets-256.59% Debt Debt-to-Equity RatioN/A Current Ratio0.71 Quick Ratio1.59 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.07) per share Price / Book-4.36Miscellaneous Outstanding Shares9,278,000Free Float9,018,000Market Cap$2.83 million OptionableNot Optionable Beta0.87 The 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:ENSC) was last updated on 5/22/2026 by MarketBeat.com Staff. From Our PartnersI wouldn't assume your portfolio is safeJC Parets, CMT and Founder of TrendLabs, warns that a 'Chaos Cycle' is forming in the market - one where damag...Trend Labs | SponsoredSneak Peek: Wall Street’s Little Black BookTom Busby, pro trader and CEO of the Diversified Trading Institute, spent years building a collection of what ...DTI Trader | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredHow to Profit from Elon’s AI lab before it goes publicElon Musk's AI lab has partnered with the Department of Defense, Oracle, and Palantir - and he just filed conf...InvestorPlace | SponsoredMaybe the Greatest Strategy of the DecadeNate Bear, Lead Technical Tactician at Monument Traders Alliance, is going public with his highest-conviction ...Monument Traders Alliance | SponsoredThe SpaceX supplier that shipped 5 billion chips to StarlinkWhen Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...Weiss Ratings | Sponsored"Computers are about to become obsolete" - George Gilder. Here’s why.George Gilder predicted the iPhone 16 years early, called Netflix a decade before it dominated streaming, and ...Eagle Publishing | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ensysce Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ensysce Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
